ReferenceMetabolic & incretin research
Survodutide
BI 456906 · GLP-1/glucagon agonist
Dual GLP-1/glucagon receptor agonist studied in metabolic and hepatic research.
About Survodutide
Survodutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic and liver-focused research models. It is used as a reference dual-agonist that pairs incretin activity with glucagon-receptor signaling. TagPep is adding survodutide as a research-use-only reference material.
Mechanism studied in research
Co-agonism at GLP-1R and GCGR — the incretin-plus-glucagon combination studied for its effects on hepatic substrate metabolism and energy balance.
Areas of research investigation
- GLP-1/glucagon co-agonism assays
- Hepatic-metabolism research models
- Energy-expenditure studies
- Comparative dual-agonist potency
Laboratory handling
Lyophilized; research reconstitution with bacteriostatic or sterile water, refrigerated storage of the solution, frozen light-protected storage of the powder.
Comparisons
Survodutide research FAQ
How does survodutide differ from retatrutide?
Survodutide is a dual GLP-1/glucagon agonist, while retatrutide adds GIP-receptor activity to make a triple agonist. Both are studied in glucagon-inclusive metabolic research.
Is survodutide available now?
It is on TagPep's research roadmap. Contact us to be notified when a documented, research-use-only batch is released.
Research use only. Survodutide is supplied as a laboratory reference material for in-vitro and research applications. It is not a drug, supplement or medical product, and is not intended for human or veterinary use, consumption, or clinical application.